These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 23127469)

  • 1. The ADAS-Cog revisited: novel composite scales based on ADAS-Cog to improve efficiency in MCI and early AD trials.
    Raghavan N; Samtani MN; Farnum M; Yang E; Novak G; Grundman M; Narayan V; DiBernardo A;
    Alzheimers Dement; 2013 Feb; 9(1 Suppl):S21-31. PubMed ID: 23127469
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alzheimer's Disease Assessment Scale-Cognitive subscale variants in mild cognitive impairment and mild Alzheimer's disease: change over time and the effect of enrichment strategies.
    Podhorna J; Krahnke T; Shear M; Harrison JE;
    Alzheimers Res Ther; 2016 Feb; 8():8. PubMed ID: 26868820
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Validation study of the Alzheimer's disease assessment scale-cognitive subscale (ADAS-Cog) for the Portuguese patients with mild cognitive impairment and Alzheimer's disease.
    Nogueira J; Freitas S; Duro D; Almeida J; Santana I
    Clin Neuropsychol; 2018; 32(sup1):46-59. PubMed ID: 29566598
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The combination of apolipoprotein E4, age and Alzheimer's Disease Assessment Scale - Cognitive Subscale improves the prediction of amyloid positron emission tomography status in clinically diagnosed mild cognitive impairment.
    Ba M; Ng KP; Gao X; Kong M; Guan L; Yu L;
    Eur J Neurol; 2019 May; 26(5):733-e53. PubMed ID: 30561868
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Alzheimer's Disease Assessment Scale-Cognitive-Plus (ADAS-Cog-Plus): an expansion of the ADAS-Cog to improve responsiveness in MCI.
    Skinner J; Carvalho JO; Potter GG; Thames A; Zelinski E; Crane PK; Gibbons LE;
    Brain Imaging Behav; 2012 Dec; 6(4):489-501. PubMed ID: 22614326
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Psychometric Evaluation of the Neuropsychological Test Battery in Individuals with Normal Cognition, Mild Cognitive Impairment, or Mild to Moderate Alzheimer's Disease: Results from a Longitudinal Study.
    Harrison JE; Rentz DM; Brashear HR; Arrighi HM; Ropacki MT; Liu E
    J Prev Alzheimers Dis; 2018; 5(4):236-244. PubMed ID: 30298182
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adding delayed recall to the Alzheimer Disease Assessment Scale is useful in studies of mild cognitive impairment but not Alzheimer disease.
    Sano M; Raman R; Emond J; Thomas RG; Petersen R; Schneider LS; Aisen PS
    Alzheimer Dis Assoc Disord; 2011; 25(2):122-7. PubMed ID: 20921876
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Validation study of the Alzheimer's Disease Assessment Scale-Cognitive Subscale for people with mild cognitive impairment and Alzheimer's disease in Chinese communities.
    Yang H; Cheng Z; Li Z; Jiang Y; Zhao J; Wu Y; Gu S; Xu H
    Int J Geriatr Psychiatry; 2019 Nov; 34(11):1658-1666. PubMed ID: 31347192
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bayesian estimation for the accuracy of three neuropsychological tests in detecting Alzheimer's disease and mild cognitive impairment: a retrospective analysis of the ADNI database.
    Wang X; Li F; Tian J; Gao Q; Zhu H
    Eur J Med Res; 2023 Oct; 28(1):427. PubMed ID: 37821912
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Psychometric Properties of Alzheimer's Disease Assessment Scale-Cognitive Subscale for Mild Cognitive Impairment and Mild Alzheimer's Disease Patients in an Asian Context.
    Zainal NH; Silva E; Lim LL; Kandiah N
    Ann Acad Med Singap; 2016 Jul; 45(7):273-83. PubMed ID: 27523508
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the utility of everyday memory test and the Alzheimer's Disease Assessment Scale-Cognitive part for evaluation of mild cognitive impairment and very mild Alzheimer's disease.
    Adachi H; Shinagawa S; Komori K; Toyota Y; Mori T; Matsumoto T; Sonobe N; Kashibayashi T; Ishikawa T; Fukuhara R; Ikeda M
    Psychiatry Clin Neurosci; 2013 Apr; 67(3):148-53. PubMed ID: 23581865
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Validation of the Hungarian version of Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) in patients with mild cognitive impairment].
    Papp E; Pákáski M; Drótos G; Kálmán J
    Psychiatr Hung; 2012; 27(6):426-34. PubMed ID: 23429337
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detecting Treatment Group Differences in Alzheimer's Disease Clinical Trials: A Comparison of Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog) and the Clinical Dementia Rating - Sum of Boxes (CDR-SB).
    Wessels AM; Dowsett SA; Sims JR
    J Prev Alzheimers Dis; 2018; 5(1):15-20. PubMed ID: 29405227
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Validation of Slovenian version of ADAS-Cog for patients with mild cognitive impairment and Alzheimer's disease.
    Ulbl J; Rakusa M
    Acta Neurol Belg; 2022 Jun; 122(3):695-702. PubMed ID: 34424494
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Derivation of a new ADAS-cog composite using tree-based multivariate analysis: prediction of conversion from mild cognitive impairment to Alzheimer disease.
    Llano DA; Laforet G; Devanarayan V;
    Alzheimer Dis Assoc Disord; 2011; 25(1):73-84. PubMed ID: 20847637
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Psychometric evaluation of ADAS-Cog and NTB for measuring drug response.
    Karin A; Hannesdottir K; Jaeger J; Annas P; Segerdahl M; Karlsson P; Sjögren N; von Rosen T; Miller F
    Acta Neurol Scand; 2014 Feb; 129(2):114-22. PubMed ID: 23763450
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Examining the reliability of ADAS-Cog change scores.
    Grochowalski JH; Liu Y; Siedlecki KL
    Neuropsychol Dev Cogn B Aging Neuropsychol Cogn; 2016 Sep; 23(5):513-29. PubMed ID: 26708116
    [TBL] [Abstract][Full Text] [Related]  

  • 18. What is the clinically relevant change on the ADAS-Cog?
    Schrag A; Schott JM;
    J Neurol Neurosurg Psychiatry; 2012 Feb; 83(2):171-3. PubMed ID: 22019547
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors of placebo group decline in the Alzheimer's disease Assessment Scale-cognitive subscale (ADAS-Cog) in 24 week clinical trials of Alzheimer's disease.
    Irizarry MC; Webb DJ; Bains C; Barrett SJ; Lai RY; Laroche JP; Hosford D; Maher-Edwards G; Weil JG
    J Alzheimers Dis; 2008 Jul; 14(3):301-11. PubMed ID: 18599956
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.